Disclosures for "Idiosyncratic Drug–induced Neutropenia Secondary to Ofatumumab Exposure in Multiple Sclerosis: A Case Report and Analysis of Food and Drug Administration Adverse Event Reporting System"
-
Ms. Viswanathan has nothing to disclose.
-
Mr. Wamuo has nothing to disclose.
-
Dr. Maynard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono.
-
Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech/Roche. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Hooshmand has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics .